coin-img-ETHETH-0.97%coin-img-SOLSOL-0.74%coin-img-BTCBTC-1.08%coin-img-PUMPPUMP-0.65%coin-img-XRPXRP-1.64%coin-img-USDCUSDC+0.00%coin-img-ADAADA+0.60%coin-img-NEARNEAR+6.40%coin-img-ETHETH-0.97%coin-img-SOLSOL-0.74%coin-img-BTCBTC-1.08%coin-img-PUMPPUMP-0.65%coin-img-XRPXRP-1.64%coin-img-USDCUSDC+0.00%coin-img-ADAADA+0.60%coin-img-NEARNEAR+6.40%coin-img-ETHETH-0.97%coin-img-SOLSOL-0.74%coin-img-BTCBTC-1.08%coin-img-PUMPPUMP-0.65%coin-img-XRPXRP-1.64%coin-img-USDCUSDC+0.00%coin-img-ADAADA+0.60%coin-img-NEARNEAR+6.40%coin-img-ETHETH-0.97%coin-img-SOLSOL-0.74%coin-img-BTCBTC-1.08%coin-img-PUMPPUMP-0.65%coin-img-XRPXRP-1.64%coin-img-USDCUSDC+0.00%coin-img-ADAADA+0.60%coin-img-NEARNEAR+6.40%
user-avatar
The Motley Fool Australia

CSL signs Alentis deal for claudin1 drug, shares trade near A$177

AI Market Summary
CSL announced an exclusive global partnership with Alentis to develop and commercialise lixudebart (claudin-1), paying US$355m upfront and funding development, with profit-sharing 55/45. The asset is in Phase 2 for a rare autoimmune kidney disease, so near-term financial impact is uncertain, but it signals continued pipeline investment and strengthens CSL's nephrology strategy alongside margin-recovery efforts in plasma-derived therapies.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-1.06%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
CSL Limited said it has struck a drug-development partnership with Alentis focused on an investigational claudin1-targeting therapy now in a Phase 2 trial for a rare autoimmune kidney disease. CSL will pay US$355 million upfront and fund the planned development program, while the companies would split global profits 55% to CSL and 45% to Alentis if the treatment reaches the market. CSL shares were trading around A$177 on Tuesday, implying a price-to-earnings multiple of just under 20 times FY27 consensus earnings per share of A$8.99, falling to about 17.5 times based on FY29 EPS of A$10.08.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.